Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Denali Hunter Data
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2401)
•••
Comment by JDavenporton Aug 31, 2022 1:21pm
120 Views
Post# 34932943

RE:RE:RE:RE:RE:RE:RE:RE:RE:Denali Hunter Data

RE:RE:RE:RE:RE:RE:RE:RE:RE:Denali Hunter DataPof, do you even remember what you're talking about?

Golly, Bioasis has a collaboration agreement with J&J/Janssen. J&J has annual revenue of almost $100 billion. What, precisely, does that mean for Bioasis? I mean, you know, at 16.5¢ per share today.

What does Chiesi's revenue have to do with Bioasis's market cap? What does it have to do with the market's opinion of the Bioasis/Chiesi agreement if that agreement remains such a secret?

I think I'll compare at least some aspects of Bioasis to Denali because, in case you haven't noticed, the two companies are pursuing the same business and their values reflect the market's relative opinions of those pursuits.

Here's a number for you. A can of No Name mushrooms at SuperStore costs $1.29. For the benefit of all, could you explain how that relates to Bioasis's market cap? It would make as much sense as...

Never mind.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities